Adenosine as a Marker and Mediator of Cardiovascular Homeostasis : A Translational Perspective
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Adenosine, a purine nucleoside, is produced broadly and implicated in the homeostasis of many cells and tissues. It signals predominantly via 4 purinergic adenosine receptors (ADORs) - ADORA1, ADORA2A, ADORA2B and ADOosine signaling, both through design as specific ADOR agonists and antagonists and as offtarget effects of existing anti-platelet medications. Despite this, adenosine has yet to be firmly established as either a therapeutic or a prognostic tool in clinical medicine to date. Herein, we provide a bench-to-bedside review of adenosine biology, highlighting the key considerations for further translational development of this proRA3 in addition to non-ADOR mediated effects. Through these signaling mechanisms, adenosine exerts effects on numerous cell types crucial to maintaining vascular homeostasis, especially following vascular injury. Both in vitro and in vivo models have provided considerable insights into adenosine signaling and identified targets for therapeutic intervention. Numerous pharmacologic agents have been developed that modulate adenmising molecule.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological disorders drug targets - 19(2019), 2 vom: 13., Seite 109-131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simard, Trevor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenosine |
|---|
| Anmerkungen: |
Date Completed 01.07.2020 Date Revised 01.07.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871529X18666181011103719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289528658 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289528658 | ||
| 003 | DE-627 | ||
| 005 | 20231225062743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871529X18666181011103719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0965.xml |
| 035 | |a (DE-627)NLM289528658 | ||
| 035 | |a (NLM)30318008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simard, Trevor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adenosine as a Marker and Mediator of Cardiovascular Homeostasis |b A Translational Perspective |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.07.2020 | ||
| 500 | |a Date Revised 01.07.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Adenosine, a purine nucleoside, is produced broadly and implicated in the homeostasis of many cells and tissues. It signals predominantly via 4 purinergic adenosine receptors (ADORs) - ADORA1, ADORA2A, ADORA2B and ADOosine signaling, both through design as specific ADOR agonists and antagonists and as offtarget effects of existing anti-platelet medications. Despite this, adenosine has yet to be firmly established as either a therapeutic or a prognostic tool in clinical medicine to date. Herein, we provide a bench-to-bedside review of adenosine biology, highlighting the key considerations for further translational development of this proRA3 in addition to non-ADOR mediated effects. Through these signaling mechanisms, adenosine exerts effects on numerous cell types crucial to maintaining vascular homeostasis, especially following vascular injury. Both in vitro and in vivo models have provided considerable insights into adenosine signaling and identified targets for therapeutic intervention. Numerous pharmacologic agents have been developed that modulate adenmising molecule | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a cardiovascular | |
| 650 | 4 | |a pre-clinical | |
| 650 | 4 | |a restenosis | |
| 650 | 4 | |a translational. | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 700 | 1 | |a Jung, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Labinaz, Alisha |e verfasserin |4 aut | |
| 700 | 1 | |a Faraz, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, F Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Di Santo, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Pitcher, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Motazedian, Pouya |e verfasserin |4 aut | |
| 700 | 1 | |a Gaudet, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Rochman, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Marbach, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Boland, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Sarathy, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Alghofaili, Saleh |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Couture, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Beanlands, Rob S |e verfasserin |4 aut | |
| 700 | 1 | |a Hibbert, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological disorders drug targets |d 2006 |g 19(2019), 2 vom: 13., Seite 109-131 |w (DE-627)NLM163039259 |x 2212-4063 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:2 |g day:13 |g pages:109-131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871529X18666181011103719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 2 |b 13 |h 109-131 | ||